PictureTel names Bond as new chief executiveVideoconferencing developer PictureTel has tapped Bruce Bond as president and CEO, effective March 1. Bond replaces Dr. Norman Gaut, who will continue to serve as chairman. Bond previously was CEO at
Videoconferencing developer PictureTel has tapped Bruce Bond as president and CEO, effective March 1. Bond replaces Dr. Norman Gaut, who will continue to serve as chairman. Bond previously was CEO at ANS, America Online's networking subsidiary that was recently sold to WorldCom.
In other PictureTel news, the Andover, MA-based firm has signed a joint development and marketing agreement with networking firm Fore Systems to develop standards-based LAN videoconferencing over ATM networks. Under the terms of the deal, Fore will develop ATM interfaces for PictureTel's family of LAN-based, H.323 videoconferencing client and server products. The addition of ATM network interfaces to the product family will enhance the quality, reliability, and performance of LAN-based videoconferencing over ATM networks, according to the firm.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.